potentially inappropriate prescribing immediately prior to
TRANSCRIPT
Potentially Inappropriate Prescribing immediately prior to Long-Term Care admission (PIP in LTC): Validation of tools for their future
use across Ontario
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine
and Bruyère Research Institute
Bruyère CLRI Webinar
March 24th, 2016
Conflict of interest declaration and sources of funding
• I have no potential conflicts of interest to declare.
• I do not accept any gifts, funding, honoraria, shares or any other forms of
payment from manufacturers of medication or medical devices, or from
providers of medical services.
• My earnings are derived from the clinical practice of medicine (Ministry of
Health and Long-Term Care of Ontario) and from academic work (University of
Ottawa).
• The work presented here is funded by the Government of Ontario through the
Bruyère Centre for Learning Research and Innovation in LTC and supported
by the Institute for Clinical Evaluative Sciences (ICES); the opinions, results
and conclusions reported in this presentation are those of the authors and are
independent from the funding sources. No endorsement by CIHR, the Ontario
MOHLTC or ICES is intended or should be inferred.
Acknowledgements
• Co-investigators: Roland Halil
Christina Catley
Barbara Farrell
Cristín Ryan
Douglas G. Manuel
• Staff: Matt Hogel
Cody D. Black
Margo Williams
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Inappropriate Prescribing
Potentially inappropriate prescribing (PIP):
“The use of medicines whose potential harms to older adults may outweigh the benefits”*
Frequent and associated with morbidity and mortality, particularly in LTC residents
*Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older
adults: results of a US consensus panel of experts.Arch Intern Med. 2003;13(22):2716–2724
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
So what is the problem?
↑ adverse events, morbidity and mortality
↑health care services use ↑costs
Aging population + ↑ vulnerability to medication adverse effects with age
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
People aged 65 years and older:*
15% of the Canadian population
40% of all retail prescription drug sales
60% of public drug program spending
*Canadian Institute for Health Information. Drug Use Among Seniors on Public Drug Programs in Canada, 2012. Ottawa, ON; 2014.
# O'Mahony D, Gallagher P, Ryan C, Byrne S, Hamilton H, Barry P, et al. STOPP & START criteria: A new approach to detecting potentially
inappropriate prescribing in old age. European Geriatric Medicine 2010;1(1):45-51.
Potentially inappropriate prescribing (PIP) in seniors – estimates from
clinical data (patients with at least one PIP):#
• 22% in the primary care setting
• 35% in the acute care hospital
• 60% in the nursing home setting
Identifying PIP
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
STOPP/START
• 80 STOPP and 34 START criteria
• Includes:
Drugs to avoid in the elderly
Drug-drug interactions
Drug-disease interactions
Drugs that increase risk of falls
Duplicate drug class prescriptions
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
STOPP/START
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
STOPP/START
• Criteria have been modified for use with health admin data
• Able to ID PIPs with frequency comparable to other studies using the full criteria
Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate
prescribing and cost outcomes for older people: a national population study. Brit J Clin
Pharmacol 2010;69(5):543-52
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Beers Criteria
• First criteria published ‘91; updated in ‘97, ‘03, ‘12
• Criticised based on:
Inclusion of obsolete/unavailable medications
Not sufficiently inclusive of common instances of PIP
Higher scores not associated with ADEs
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Beers Criteria
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Starting from the end…
85% of prescriptions are written by
primary care physicians → Target for interventions
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
“Transparent evidence,
rational use,
equitable access”
Monitoring of prescribing quality
and related patient outcomes
Development of targeted
strategies for CME about
common and/or costly PIPs
Point of care access to medication
information for all patients
(health administrative data)
Development of feedback
mechanisms for prescribers
Doing this at the population level …requires population-level data
How well do these criteria perform in Health Admin Data?
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
The PIP in Long-Term Care (LTC) study:
To validate medication appropriateness criteria
applicable to health administrative data by comparing
their performance when applied to clinical data
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Study goal:
*Bjerre LM, Halil R, Catley C, et al. Potentially inappropriate prescribing (PIP) in
long-term care (LTC) patients: validation of the 2014 STOPP-START and 2012 Beers
criteria in a LTC population—a protocol for a cross-sectional comparison of clinical
and health administrative data. BMJ Open 2015;5:e009715. doi:10.1136/bmjopen-
2015-009715
The PIP in Long-Term Care (LTC) study
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Study Participants
• Recruiting newly admitted residents to LTC, convalescent, or respite care after June 2014 from 6 LTC homes in Ottawa area
Individuals providing informed consent
Aged 66+
OHIP-eligible
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Recruitment to date
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
110 having informed consent conversation
92 agreeing to participate
Final Study Group
n= 87
Declined to participate
n= 8
Could not be contacted
n= 99
Prospective participant is deceased
n= 10
Patient was previously in another LTC
n= 3
Patient deceased before data could be collected
n= 2
209 willingness to be contacted forms received
Data Collection – Clinical Data
• Charts abstracted by a contracted pharmacist
• Excel-based data collection template created
• Prompts entry of relevant patient data
• Responds to data entry by directing evaluator toward most pertinent PIPs
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Data collection sheet
McLaughlin Centre for Population Health Risk Assessment
Snapshot – PIP identified via clinical data
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
*Bjerre LM, Halil R, Catley C, et al. Potentially inappropriate prescribing (PIP) in long-term care (LTC) patients: validation of the
2014 STOPP-START and 2012 Beers criteria in a LTC population—a protocol for a cross-sectional comparison of clinical and
health administrative data. BMJ Open 2015;5:e009715. doi:10.1136/bmjopen-2015-009715
Bjerre LM, Halil R, Catley C, et al. Potentially inappropriate prescribing (PIP) in long-term care (LTC) patients: validation of the 2014 STOPP-START
and 2012 Beers criteria in a LTC population—a protocol for a cross-sectional comparison of clinical and health administrative data. BMJ Open
2015;5:e009715. doi:10.1136/bmjopen-2015-009715
Snapshot – PIP identified via clinical data
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Data Type Clinical Data Health Administrative Data
Medication Assessment Tools # PIP # PIP/Pt % PIP (actual/
maximum)
% of patients with one or
more PIP # PIP # PIP/Pt % PIP (actual/
maximum)
% of patients with one or
more PIP
Full STOPP/START 2014 312 3.76 3.27 % 20.48 %
Subset of STOPP/START HA Data
Subset of STOPP/START clinical data 165 1.99 3.26 % 19.28 %
Full Beers 2012 157 1.89 3.44 % 14.46 %
Subset of Beers 2012 HA data
Subset of Beers 2012 clinical data 154 1.86 3.71 % 14.46 %
Snapshot – Most frequent PIP identified via clinical data
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Criterion Definition Prevalence
START E5 Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is > -1.0 but < -2.5 in multiple sites).
41%
START I2 2. Pneumococcal vaccine at least once after age 65 according to national guidelines. 33%
Beers Diag B3
Dementia and cognitive impairment --> Anticholinergics (see Table 9 in the original
guideline document for full list)
Benzodiazepines
H2-receptor antagonists
Zolpidem Antipsychotics, chronic and as-needed use --> Avoid
31%
Beers Caut A4
Antipsychotics
Carbamazepine
Carboplatin
Cisplatin
Mirtazapine
SNRIs
SSRIs
TCAs Vincristine --> Use with caution
29%
Criterion Definition Prevalence
START E3 Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites).
27%
STOPP K2 Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 22%
START I1 Seasonal trivalent influenza vaccine annually. 22%
Beers Diag B4
History of falls or fractures --> Anticonvulsants
Antipsychotics
Benzodiazepines
Nonbenzodiazepine hypnotics
Eszopiclone, Zaleplon, Zolpidem
TCAs/SSRIs --> Avoid unless safer alternatives are not available; avoid anticonvulsants except for seizure
22%
START A6 Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease.
19%
STOPP A1 Any drug prescribed without an evidence-based clinical indication
16%
Snapshot – Most frequent PIP identified via clinical data
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Data Collection – Administrative Data
• 5 databases accessible to the Institute for Clinical and Evaluative Sciences
ODBD – Drug claims
DAD – Acute care hospitalizations
NACRS – Emergency department visits
OHIP – Claims paid by ON health insurance
RPDB – Birth and death dates
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
• From clinical criteria to SAS code…
From criteria to SAS code…
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Section B: Cardiovascular
System
3. Beta-blocker in combination
with verapamil or diltiazem (risk
of heart block).
DIN lists
SAS code
ICD-10
diagnostic codes
Snapshot of Results – Patient Profiles
11 of 64 linked patients have hospitalizations immediately prior to LTC admission
* Mock profile based on patterns commonly seen in data.
*
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Snapshot of Results –Benzodiazepine (K1) Drug Profiles
* Mock profile based on patterns commonly seen in data.
*
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Snapshot of Results – Comparing HA and clinical data
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Health administrative data
Clinical data PIP No PIP
PIP Concordant
(A)
Discordant
(B)
No PIP Discordant
(C)
Concordant
(D)
Total
(=A+B+C+D)
Error in coding?
Hospitalization or
CCC bed?
Error in self-report
by pt or care-giver?
Rx dispensed but not taken?
Snapshot of Results –Benzodiazepines The distribution of PIP and non-PIP detected from HAD, clinical data, and both HAD and
clinical data if PIP were investigated in 100 people for Criterion K1. Concordant = 75%, Discordant=25%
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Snapshot of Results – Neuroleptic (K2) Drug Profiles
* Mock profile based on patterns commonly seen in data.
*
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Snapshot of Results – Neuroleptics The distribution of PIP and non-PIP detected from HAD, clinical data, and both HAD and
clinical data if PIP were investigated in 100 people for Criterion K2. Concordant = 67%, Discordant=33%
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Snapshot of Results – PPI > 8 weeks (F2) Drug Profiles
* Mock profile based on patterns commonly seen in data.
*
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Snapshot of Results – Neuroleptics The distribution of PIP and non-PIP detected from HAD, clinical data, and both HAD and
clinical data if PIP were investigated in 100 people for Criterion F2. Concordant = 75%, Discordant=25%
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Next Steps
• Completion of analyses for all STOPP/START and Beers criteria (coding nearing completion) using both patient clinical data with health administrative data
• Presentation/dissemination/publication of full results
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
What else? The PIP-STOPP study
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Goals:
To describe the occurrence of PIP in Ontario’s older population, and assess the health outcomes and health system costs associated with it.
• Population-based retrospective cohort study using Ontario’s large health
administrative and population databases.
• Eligible patients aged 66 years and older who were issued at least one
prescription between April 1st 2003 and March 31st 2014,
(approximately 2 million patients) will be included.
PIP
ED visits hospitalizations
death adverse drug events
PIP-STOPP study: Next steps
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine
Analyses Dissemination
Stakeholder engagement
Questions?
THANK YOU!
Dr. Lise M. Bjerre, MD, PhD [email protected]
University of Ottawa, Department of Family Medicine